CADL (Candel) Quarterly Revenue Growth

Public company logo of Candel (CADL)

Candel Therapeutics (CADL) operates in the high-risk oncolytic virus segment, facing intense pressure from pharmaceutical behemoths. A lack of profitability and high laboratory costs leave the company dependent on clinical trial outcomes. However, the brand is valued for its safe methods of targeted tumor destruction. The quarterly revenue growth trajectory clearly demonstrates income dynamics, where the value is recorded at 0.00.

CADL (Candel Therapeutics) Quarterly Revenue Growth Rate history from 07/04/2022 to 11/20/2026

Analytical breakdowns for candeltx.com (CADL)

Summary company analytics:Candel (CADL)
Flagship merchandise of Candel Therapeutics

The indicator is based on a dynamic comparison of current operating revenues against the figures from the preceding quarter. This metric captures the rate of change in cash flow, allowing for the detection of business stagnation prior to the publication of financial reports. For Candel Therapeutics (CADL), this is critically important when scaling its network of oncology centers to meet the demand for immunotherapy. Analyzing quarterly revenue growth rates helps identify a slowdown in expansion in a timely manner and avoid capital losses.

Competing companies

BeiGene Oncology - Quarterly Revenue Growth|HALO: Revenue Growth QoQ|Revolution Medicines Corp (RVMD) - Revenue Growth QoQ|Quarterly Revenue Growth Rate Ascentage Pharma Group International (AAPG)|Revenue Growth QoQ CG Oncology, Inc.|Quarterly Revenue Growth Rate UroGen Pharma Corp URGN|Quarterly Revenue Growth BCAX|Personalis, Inc. - Sales Growth QoQ|Erasca - Quarterly Sales Growth|Quarterly Revenue Increase DCTH|YMAB: Quarterly Sales Growth|Quarterly Revenue Growth Rate Aura Corp|ARAY: Quarterly Revenue Growth|Revenue Dynamics QoQ SLS (SELLAS Life Sciences Group, Inc.)|ACTU (Actuate Therapeutics) - Quarterly Revenue Growth|Quarterly Sales Growth Citius Oncology Inc. (CTOR)|Revenue Growth QoQ TuHURA (HURA)|TARA - Quarterly Revenue Growth Rate|Quarterly Revenue Growth FATE (Fate Therapeutics Inc)|Aadi Bioscience Inc (WHWK) - Quarterly Revenue Growth Rate|TScan - Quarterly Revenue Growth|Champions Oncology, Inc. (CSBR) - Quarterly Sales Growth|XBIT (XBiotech Inc.) - Quarterly Sales Growth|CEL-SCI Corporation (CVM) - Quarterly Revenue Growth|Revenue Growth QoQ OS Therapies|RADX: Quarterly Revenue Increase|Revenue Growth QoQ artivabio.com (ARTV)|Quarterly Sales Growth Rate Adlai Nortye|Quarterly Revenue Growth VERU (Veru Corporation)|Sales Change QoQ TPST (Tempest Tx)|XLO: Quarterly Sales Growth|renovarobio.com (RENB) - Quarterly Sales Growth|Mural Bio (MURA) - Revenue Growth QoQ|Kairos Pharma Inc (KAPA) - Quarterly Revenue Growth|Quarterly Sales Growth OKUR|CytoMed Therapeutics (GDTC) - Quarterly Sales Growth Rate|Quarterly Sales Growth CRIS (Curis Inc.)|Quarterly Revenue Growth Apollomics Inc. (APLM)|Revenue Growth QoQ Tharimmune Corp THAR|Advanced Biomed Corp - Revenue Growth QoQ|GNPX: Quarterly Sales Growth|Calidi Biotherapeutics, Inc. (CLDI) - Quarterly Sales Growth|SBFM: Quarterly Revenue Growth|Quarterly Sales Growth Xenetic Biosciences Inc.|Revenue Growth QoQ Salarius Pharmaceuticals Inc|PPBT: Quarterly Revenue Increase|Quarterly Revenue Growth AONC|BGNE (BeOne Medicines) - Quarterly Revenue Increase|Checkpoint Therapeutics, Inc - Quarterly Sales Growth|elevationoncology.com (ELEV) - Quarterly Revenue Growth Rate|iCAD Inc. - Quarterly Revenue Growth|Quarterly Revenue Growth Rate Ikena Oncology|NTBL: Quarterly Revenue Growth|Quarterly Revenue Growth Rate Viracta (VIRX)|MOR (MorphoSys AG) - Quarterly Revenue Growth|NAYA: Quarterly Revenue Increase|Revenue Growth QoQ Ascentage Pharma Group Ltd (AAPGV)